Premium
CRVO treatments in 2014
Author(s) -
GLACETBERNARD A
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2014.1712.x
Subject(s) - medicine , central retinal vein occlusion , macular edema , neovascular glaucoma , ophthalmology , retinal vein , glaucoma , occlusion , retinal , surgery , diabetic retinopathy , diabetes mellitus , endocrinology
Abstract Although central retinal vein occlusion (CRVO) accounts for a minority of retinal vein occlusions, it is associated with more severe vision loss and with the vision‐threatening risk of neovascular glaucoma. The newly available treatments for macular edema have considerably improved visual outcome of many CRVO patients. Nevertheless, the evaluation of the ischemic component remains essential. The presentation will include when to perform laboratory workup for systemic disease and how macular edema treatment could be combined with classical treatment (etiologic treatment such as hemodilution, treatment of non‐perfusion area with laser photocoagulation).Commercial interest